Zoliflodacin
Chemical compound
From Wikipedia, the free encyclopedia
Zoliflodacin, sold under the brand name Nuzolvence, is an antibiotic used for the treatment of antibiotic-resistant Neisseria gonorrhoeae (gonorrhea).[2] Zoliflodacin is being developed as part of a public-private partnership between Innoviva Specialty Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP).[3] Zoliflodacin is taken by mouth.[2]
| |
| Clinical data | |
|---|---|
| Trade names | Nuzolvence |
| Other names | AZD0914; ETX0914 |
| AHFS/Drugs.com | nuzolvence |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Antibacterial |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 97.8% |
| Metabolism | Liver |
| Onset of action |
|
| Elimination half-life | 5.3–6.3 h |
| Excretion | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H22FN5O7 |
| Molar mass | 487.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common side effects include low white blood cell counts, headache, dizziness, nausea, and diarrhea.[2]
Zoliflodacin was approved for medical use in the United States in December 2025.[2]
Medical uses
Zoliflodacin is indicated for the treatment of uncomplicated urogenital gonorrhea in people who weigh at least 77 pounds (35 kg).[2]
Susceptible bacteria
Zoliflodacin has shown in vitro activity against the following species of bacteria:[4] Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Chlamydia trachomatis
Adverse effects
Animal studies showed that zoliflodacin might cause birth defects, pregnancy loss, or male fertility problems.[2]
Mechanism of action
Zoliflodacin is a spiropyrimidinetrione antibacterial agent (first-in-class) that inhibits bacterial type II topoisomerases, including DNA gyrase and topoisomerase IV.[5] It binds to these enzymes at a site that is distinct from fluoroquinolone binding sites, leading to inhibition of DNA replication and bacterial cell death.[6] This novel mechanism confers activity against strains resistant to other topoisomerase inhibitors and involves inhibition of bacterial type II topoisomerases.[4][7]
History
A high throughput screening campaign aimed at identifying compounds with whole cell antibacterial activity performed at Pharmacia & Upjohn identified compound PNU-286607, a progenitor of Zoliflodacin, as having the desired activity.[8]
Subsequent research at AstraZeneca led to the discovery that the nitroaromatic in PNU-286607 could be replaced with a fused benzisoxazole ring,[9] which allowed for an exploration of different groups at the 3-position of the heterocycle. This work was continued at Entasis Pharmaceuticals where extensive optimization resulted in the discovery of ETX0914.[4]
Researchers tested zoliflodacin in a study with 930 participants who had uncomplicated urogenital gonorrhea.[2] Two-thirds of participants received a single 3-gram dose of zoliflodacin dissolved in water.[2] The other third received the standard treatment of ceftriaxone shot plus azithromycin pill.[2] The study measured how well the medicines cleared the bacteria 4 to 8 days after treatment.[2] The study showed 91% of participants who took zoliflodacin were cured and 96% of participants who received the standard treatment were cured.[2]
Society and culture
Legal status
Zoliflodacin was approved for medical use in the United States in December 2025.[3][10]
The US Food and Drug Administration (FDA) granted the application for zoliflodacin fast track, qualified infectious disease product, and priority review designations for the uncomplicated urogenital gonorrhea indication.[2] The FDA approval for zoliflodacin was granted to Entasis Therapeutics.[2]
Names
Zoliflodacin is the international nonproprietary name.[11]
Zoliflodacin is sold under the brand name Nuzolvence.[3]
